Akebia Therapeutics CEO resigns
- Nicholas Grund resigns as Chief Commercial Officer
- Resignation effective November 6, 2026
- Consulting agreement until April 30, 2027
AKBA
Akebia Therapeutics, Inc. SEC filings
Every EDGAR filing for Akebia Therapeutics, Inc. (AKBA), newest first, with AI summaries and stories.
- Ticker
- AKBA
- CIK
- 1517022
- Sector
- Biotech and pharma
- Latest filing
- 5d
Next: earnings expected ~Nov 9 · 10-Q expected ~Nov 9 (deadline Nov 9)
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
MAJOR8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINE4Akebia Therapeutics, Inc.AKBALIVE John P. Butler, insider filing for AKBA
John P. Butler, reporting
ROUTINES-8Akebia Therapeutics, Inc.AKBALIVE NOTABLE10-QAkebia Therapeutics, Inc.AKBALIVE ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINE4Akebia Therapeutics, Inc.AKBALIVE Erik Ostrowski, insider filing for AKBA
Erik Ostrowski, reporting
ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINE144Akebia Therapeutics, Inc.AKBALIVE Erik Ostrowski, planned sale of AKBA shares
Erik Ostrowski, reporting
ROUTINE4Akebia Therapeutics, Inc.AKBALIVE 6 insider filings
Myles Wolf, insider filing for AKBA
Show all 6
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
Myles Wolf, reporting
ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINESCHEDULE 13GAkebia Therapeutics, Inc.AKBALIVE Ownership stake disclosure by STATE STREET CORP
STATE STREET CORP, filed by
NOTABLE10-QAkebia Therapeutics, Inc.AKBALIVE ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINEDEF 14AAkebia Therapeutics, Inc.AKBALIVE ROUTINEDEFA14AAkebia Therapeutics, Inc.AKBALIVE ROUTINEPRE 14AAkebia Therapeutics, Inc.AKBALIVE ROUTINE4Akebia Therapeutics, Inc.AKBALIVE 2 insider filings
Philip J. Vickers, insider filing for AKBA
Show all 2
- 4Insider filing for AKBA
- 3New insider at AKBA
Philip J. Vickers, reporting
ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINESCHEDULE 13G/AAkebia Therapeutics, Inc.AKBALIVE Ownership stake disclosure by VANGUARD GROUP INC (amended)
VANGUARD GROUP INC, filed by
ROUTINE4Akebia Therapeutics, Inc.AKBALIVE John P. Butler, insider filing for AKBA
John P. Butler, reporting
NOTABLE10-KAkebia Therapeutics, Inc.AKBALIVE ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINESCHEDULE 13GAkebia Therapeutics, Inc.AKBALIVE Ownership stake disclosure by STATE STREET CORP
STATE STREET CORP, filed by
ROUTINE4Akebia Therapeutics, Inc.AKBALIVE 6 insider filings
Richard C Malabre, insider filing for AKBA
Show all 6
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
Richard C Malabre, reporting
ROUTINE4Akebia Therapeutics, Inc.AKBALIVE 7 insider filings
Nicholas Grund, insider filing for AKBA
Show all 7
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 4Insider filing for AKBA
- 3New insider at AKBA
Nicholas Grund, reporting
ROUTINE144Akebia Therapeutics, Inc.AKBALIVE 5 Form 144 notices
Erik Ostrowski, planned sale of AKBA shares
Show all 5
- 144Planned insider sale of AKBA shares
- 144Planned insider sale of AKBA shares
- 144Planned insider sale of AKBA shares
- 144Planned insider sale of AKBA shares
- 144Planned insider sale of AKBA shares
Erik Ostrowski, reporting
ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE ROUTINESCHEDULE 13G/AAkebia Therapeutics, Inc.AKBALIVE Ownership stake disclosure by BlackRock, Inc. (amended)
BlackRock, Inc., filed by
ROUTINE8-KAkebia Therapeutics, Inc.AKBALIVE